SDS Opticv has an agreement supporting the implementation of i.a. inPROBE technology in Germany

SDS Optic has signed an agreement with the German company biosaxony Management GmbH for participation in the Medical Forge Leipzig acceleration program, the company announced. As part of the program, the company will receive support with a total value of PLN 214,000. euro. The aim of the program is to help implement innovative technologies, such as inPROBE, on the German market.

The agreement with biosaxony assumes support for SDS Optic in the process of introducing the inPROBE technology to the German market, including the development of technical, legal and commercialization documentation for the medical device and the promotion of the company’s technology. biosaxony also provides the opportunity to use the laboratory and office infrastructure in Leipzig, as well as e.g. personal counseling and access to advanced training. The planned activities also included establishing contact with a network of German clinics in order to receive important feedback on the development and commercialization of technology tailored to the needs of Western European markets.

“Signing the contract with biosaxony is the culmination of a several-month, multi-stage qualification process. As a result, the company was among the 8 companies selected to participate in the 2023 edition. The following areas were assessed as part of the qualification: the importance of a clinical need; market potential of the technology; team; convergence of goals with Medical Forge; transparency of communication. We are glad that another recognized entity in the industry noticed and appreciated the potential of the inPROBE platform. Cooperation with biosaxony will make it easier for us, among others, to: building a contact network with German clinics, hospitals and laboratories, as well as developing a contact network for the needs of future commercialization and distribution of our groundbreaking solutions,” said COO SDS Optic Mateusz Sagan, quoted in the release.

The company, with own contribution of PLN 21 thousand. EUR, will receive, under the acceleration program, access to the services of the biosaxony partner network worth PLN 189,000. EUR and additional funding in the amount of PLN 25,000. euro. The total amount of support will be PLN 214,000. euro


SDS Optic is a company developing proprietary inPROBE technology platform for real-time medical diagnostics in cancer, infectious, viral, bacterial and fungal diseases. The company debuted on the NewConnect market in 2022.


Our privacy policy